Abstract
Excision Repair Cross-Complementing Rodent Repair Group 2 (ERCC2) plays an important role in DNA repair by eliminating bulky DNA adducts produced by platinum agents during the nucleotide excision repair pathway. Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity. This study examined ERCC2 polymorphisms and haplotype structure across 18.9 kb in 95 European, 95 African, and 95 Asian individuals. Single-nucleotide polymorphisms (SNPs) (ERCC2 −9164 A>T, −1989 A>G, −516 G>A, 468 C>A [Arg156Arg], 1737 C>T [Val579Val], 2133 C>T [Asp711Asp], and 2251 T>G [Lys751Gln]) were mined and mapped using Golden Path, PolyMAPr, and Promolign. Genotyping was performed using PCR and pyrosequencing. Allele frequencies ranged from 0 to 0.47 (Europeans), 0.05 to 0.72 (Africans), and 0 to 0.47 (Asians). The synonymous cSNP at codon 579 could not be confirmed in our populations. There were significant differences in haplotype structure and frequency between populations. This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lamerdin JE, Stilwagen SA, Ramirez MH, Stubbs L, Carrano AV . Sequence analysis of the ERCC2 gene regions in human, mouse, and hamster reveals three linked genes. Genomics 1996; 34: 399–409.
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ . A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654–8658.
Liang G, Xing D, Miao X, Tan W, Yu C, Lu W et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003; 105: 669–673.
de Laat WL, Jaspers NG, Hoeijmakers JH . Molecular mechanism of nucleotide excision repair. Genes Dev 1999; 13: 768–785.
Watters JW, McLeod HL . Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 2003; 1603: 99–111.
Drapkin R, Reardon JT, Ansari A, Huang JC, Zawel L, Ahn K et al. Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 1994; 368: 769–772.
Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, Grossman L et al. Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001; 61: 7430–7434.
Frederick GD, Amirkhan RH, Schultz RA, Friedberg EC . Structural and mutational analysis of the Xeroderma pigmentosum group D (XPD) gene. Hum Mol Genet 1994; 3: 1783–1788.
Broughton BC, Steingrimsdottir H, Weber CA, Lehmann AR . Mutations in the Xeroderma pigmentosum group D DNA repair/transcription gene in patients with trichothiodystrophy. Nat Genet 1994; 7: 189–194.
Bootsma D, Hoeijmakers JH . The molecular basis of nucleotide excision repair syndromes. Mutat Res 1994; 307: 15–23.
Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett 2003; 191: 171–178.
Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354–1357.
Johnson NP, Hoeschele JD, Rahn RO, O'Neill JP, Hsie AW . Mutagenicity, cytotoxicity, and DNA binding of platinum(II)-chloroamines in Chinese hamster ovary cells. Cancer Res 1980; 40: 1463–1468.
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23–30.
Goldberg R . Oxaliplatin in colorectal cancer: current studies. Oncology 2000; 14: 42–47.
Weinshilboum R, Wang L . Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther 2004; 75: 253–258.
Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121–132.
Uno Y, Sakamoto Y, Yoshida K, Hasegawa T, Hasegawa Y, Koshino T et al. Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J Hum Genet 2003; 48: 594–597.
Freimuth RR, Stormo GD, McLeod HL . PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat, in press.
Zhao T, Chang L-W, McLeod HL, Stormo GD . PromoLign: A database for upstream region analysis and SNPs. Hum Mutat 2004; 23: 534–539.
McLeod HL, Syvanen AC, Githang'a J, Indalo A, Ismail D, Dewar K et al. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 1998; 8: 195–199.
Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL . Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367–370.
Rose CM, Marsh S, Ameyaw MM, McLeod HL . Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol Med 2003; 85: 225–237.
Incorporation AB . Relative quantification of gene expression. User Bulletin No. 2 1997.
Pfaffl MW . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
Yu J, Marsh S, Ahluwalia R, McLeod HL . Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res 2003; 63: 6170–6173.
Schaid DJ, McDonnell SK, Wang L, Cunningham JM, Thibodeau SN . Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am J Hum Genet 2002; 71: 992–995.
Ke X, Cardon LR . Efficient selective screening of haplotype tag SNPs. Bioinformatics 2003; 19: 287–288.
Acknowledgements
This work was supported by the NIH Pharmacogenetics Research Network (GM63340; http://pharmacogenetics.wustl.edu) and the Siteman Cancer Center (P30CA091842). These data have been deposited in the Pharmacogenetics Knowledge Base (http://www.pharmgkb.org/).
Author information
Authors and Affiliations
Corresponding author
Additional information
SUPPLEMENTARY INFORMATION
Supplementary Information accompanies the paper on TPJ website http://www.nature.com/tpj).
Supplementary information
Rights and permissions
About this article
Cite this article
King, C., Yu, J., Freimuth, R. et al. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J 5, 54–59 (2005). https://doi.org/10.1038/sj.tpj.6500283
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500283
Keywords
This article is cited by
-
Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis
Tumor Biology (2014)
-
DNA repair gene polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis
Chinese Journal of Cancer Research (2011)
-
Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer
Breast Cancer Research and Treatment (2010)
-
The Polymorphism of DNA Repair Gene ERCC2/XPD Arg156Arg and Susceptibility to Breast Cancer in a Chinese Population
Biochemical Genetics (2009)